Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$1.00
-2.0%
$1.04
$0.71
$1.61
$63.86M1.1998,506 shs33,076 shs
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
$3.02
+0.3%
$3.05
$1.93
$4.39
$255.31M0.9942,966 shs24,931 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$4.45
+0.2%
$3.75
$0.52
$5.92
$293.55M1.851.08 million shs810,067 shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$18.73
-0.3%
$9.85
$8.15
$22.18
$522.97M2.07868,523 shs788,374 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
+2.00%-1.92%-19.05%-12.07%-0.49%
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
-1.31%-1.95%+1.01%+14.02%+44.02%
Neuronetics, Inc. stock logo
STIM
Neuronetics
+5.21%+23.33%+29.45%+4.72%+132.46%
ZimVie Inc. stock logo
ZIMV
ZimVie
+0.27%+115.37%+117.11%+99.36%-14.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
1.7407 of 5 stars
3.51.00.00.02.50.00.6
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
2.4753 of 5 stars
3.55.00.00.00.61.70.0
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.4468 of 5 stars
2.31.00.00.03.21.70.6
ZimVie Inc. stock logo
ZIMV
ZimVie
0.6803 of 5 stars
1.32.00.00.02.51.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
3.00
Buy$5.50450.00% Upside
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
3.00
Buy$8.00164.90% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.67
Moderate Buy$5.5023.60% Upside
ZimVie Inc. stock logo
ZIMV
ZimVie
2.50
Moderate Buy$17.00-9.24% Downside

Current Analyst Ratings Breakdown

Latest CTSO, DRTS, STIM, and ZIMV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$9.00 ➝ $19.00
7/21/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/25/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/15/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/15/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00
5/15/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $10.00
5/2/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/29/2025
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$35.60M1.76N/AN/A$0.20 per share5.00
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
N/AN/AN/AN/A$0.89 per shareN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
$74.89M3.93N/AN/A$0.57 per share7.81
ZimVie Inc. stock logo
ZIMV
ZimVie
$449.75M1.16$1.85 per share10.11$13.83 per share1.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/12/2025 (Estimated)
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
-$31.75M-$0.46N/AN/AN/AN/A-49.48%-36.69%8/13/2025 (Estimated)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$43.71M-$1.31N/AN/AN/A-53.67%-174.15%-38.41%8/5/2025 (Estimated)
ZimVie Inc. stock logo
ZIMV
ZimVie
-$25.83M-$0.71N/AN/A-4.40%5.53%2.84%8/7/2025 (Estimated)

Latest CTSO, DRTS, STIM, and ZIMV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
-$0.12N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.07N/AN/AN/A$9.79 millionN/A
8/7/2025Q2 2025
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.2285N/AN/AN/A$112.82 millionN/A
8/5/2025Q2 2025
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.08N/AN/AN/A$36.80 millionN/A
5/19/2025Q1 2025
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
-$0.14-$0.12+$0.02-$0.12$0.03 millionN/A
5/14/2025Q1 2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million
5/8/2025Q1 2025
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.21$0.27+$0.06-$0.05$113.10 million$112.00 million
5/6/2025Q1 2025
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.13-$0.21-$0.08-$0.21$29.07 million$31.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
0.98
2.61
2.30
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
0.10
5.81
5.81
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.40
2.44
2.28
ZimVie Inc. stock logo
ZIMV
ZimVie
0.58
2.14
1.48

Institutional Ownership

CompanyInstitutional Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
32.87%
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
2.65%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%
ZimVie Inc. stock logo
ZIMV
ZimVie
95.63%

Insider Ownership

CompanyInsider Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
7.30%
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
39.50%
Neuronetics, Inc. stock logo
STIM
Neuronetics
8.70%
ZimVie Inc. stock logo
ZIMV
ZimVie
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
22062.61 million58.04 millionOptionable
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
8084.82 million51.32 millionNo Data
Neuronetics, Inc. stock logo
STIM
Neuronetics
18066.11 million60.36 millionOptionable
ZimVie Inc. stock logo
ZIMV
ZimVie
1,77027.85 million27.01 millionOptionable

Recent News About These Companies

ZimVie (NASDAQ:ZIMV) Upgraded to "Equal Weight" at Barclays
ZimVie (NASDAQ:ZIMV) Shares Gap Up - Should You Buy?
BC-Most Active Stocks
...
ZimVie Inc to be Acquired by ARCHIMED
Wall Street Zen Downgrades ZimVie (NASDAQ:ZIMV) to Buy
ZimVie: Screening Cheap (Rating Upgrade)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cytosorbents stock logo

Cytosorbents NASDAQ:CTSO

$1.00 -0.02 (-1.96%)
Closing price 04:00 PM Eastern
Extended Trading
$1.01 +0.01 (+1.20%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Alpha Tau Medical stock logo

Alpha Tau Medical NASDAQ:DRTS

$3.02 +0.01 (+0.33%)
Closing price 04:00 PM Eastern
Extended Trading
$3.02 +0.00 (+0.17%)
As of 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Neuronetics stock logo

Neuronetics NASDAQ:STIM

$4.45 +0.01 (+0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$4.46 +0.01 (+0.22%)
As of 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

ZimVie stock logo

ZimVie NASDAQ:ZIMV

$18.73 -0.05 (-0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$18.73 0.00 (0.00%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.